The Smokeless Surge: How Nicotine Pouches Are Sweeping the Nation and How the Government is Responding

Over the past few years, a massive shift has occurred in how Americans consume nicotine. Stepping away from combustible cigarettes and even traditional vaping, millions of adults are turning to a discreet, smoke-free, and spit-free alternative: the nicotine pouch.

Brands like ZYN, on!, and VELO have become ubiquitous. The global market for these small, synthetic fiber pouches was valued at over $7 billion in 2024 and is projected to explode to roughly $44 billion by 2034. But as these products sweep across the country, driven by a desire for harm reduction, discreet usage in the workplace, and a wide array of flavors, how exactly is the government monitoring and regulating this booming industry, and what are the actual health implications?

Here is a breakdown of the current regulatory landscape and health effects of nicotine pouches in the United States.

The Role of the FDA

In the U.S., nicotine pouches are regulated by the Food and Drug Administration (FDA) through its Center for Tobacco Products. Because they contain nicotine, they are legally classified and regulated as tobacco products under the 2009 Family Smoking Prevention and Tobacco Control Act, even if the nicotine is synthetically derived and contains no actual tobacco leaf.

To legally market a new tobacco product in the U.S., companies must submit a Premarket Tobacco Product Application (PMTA). To get the green light, manufacturers must prove to the FDA that permitting the sale of their product is “appropriate for the protection of the public health”—meaning the benefits to adult smokers looking to transition away from cigarettes outweigh the risks of introducing the product to non-users and youth.

Recent Historic Authorizations

For a long time, nicotine pouches operated in a regulatory gray area while the FDA waded through millions of applications. However, 2025 marked a watershed year for the industry:

• The ZYN Authorization (January 2025): In a first-of-its-kind decision, the FDA officially authorized the marketing of 20 specific ZYN products (covering various flavors and two strengths: 3mg and 6mg). After rigorous scientific review, the agency concluded that ZYN poses a significantly lower risk of cancer and other serious health conditions compared to traditional cigarettes and moist snuff.

• The “on!” Authorization and Pilot Program (December 2025): Late in the year, the FDA authorized six “on!” nicotine pouch products. Notably, these were the first authorizations granted under a new FDA Pilot Program launched in September 2025. Recognizing that nicotine pouches sit lower on the “continuum of risk” compared to combustible tobacco, this pilot program was designed to streamline and fast-track the PMTA review process for pouches.

Health Effects: What We Know So Far

While the FDA has authorized certain pouches under the premise of harm reduction for existing smokers, health agencies like the Centers for Disease Control and Prevention (CDC) stress a fundamental baseline: there is no such thing as a safe tobacco product. Because nicotine pouches only entered the U.S. market in 2016, scientists are still actively studying their long-term health impacts.

However, the immediate health concerns center heavily on the intense addictiveness of the pouches. The CDC notes that products can contain high levels of nicotine, a chemical that is particularly dangerous for youth, young adults, and pregnant women. Specifically, the CDC warns that:

• Fetal Toxicity: Nicotine is toxic to developing fetuses and poses a clear health danger during pregnancy.

• Brain Development: For young people, nicotine can actively harm brain development, a process that continues until about age 25. Regular exposure during adolescence can permanently affect the parts of the brain responsible for attention, learning, mood, and impulse control.

• Future Addiction Risks: Adolescents who use nicotine pouches can begin showing signs of addiction very rapidly, placing them at an increased risk for future addiction to other drugs.

It is also crucial to note that the FDA explicitly states these products are authorized for marketing, not approved as safe or as medical smoking cessation aids. The FDA does not recognize nicotine pouches as a treatment to help people quit smoking (unlike nicotine patches or gums, which are regulated as drugs).

Strict Guardrails and the Youth Factor

A primary concern surrounding the rise of nicotine pouches is their appeal to youth, largely due to flavors like mint, citrus, and coffee. To combat this, the FDA’s recent authorizations come with severe stipulations:

• Age and Marketing: Sales are strictly restricted to adults 21 and older. Companies face stringent marketing restrictions, including a ban on mass-market TV and radio advertising and requirements to ensure digital ads are carefully age-gated.

• Child-Resistant Packaging: Following a rise in accidental ingestions by toddlers, the FDA now strongly urges manufacturers to utilize child-resistant packaging.

• Monitoring: The FDA continually monitors youth usage. Despite widespread fears of a “Zyn-demic” among teens, recent data from the 2025 National Youth Tobacco Survey indicated that youth usage of nicotine pouches actually dropped slightly from 1.8% in 2024 to 1.7% in 2025. However, the FDA retains the right to yank a product’s authorization if youth initiation spikes.

The State and Local Battleground

While the FDA handles federal regulation, the legal landscape is complicated by state and local governments.

Even though the FDA has federally authorized certain flavored pouches, local municipalities can still enforce their own laws. For example, Washington D.C. and states like California have strict bans on the sale of flavored tobacco products. In 2024, the makers of ZYN had to pay a $1.2 million settlement to Washington D.C. for violating the district’s flavor ban, resulting in the company halting all direct-to-consumer online sales nationwide to restructure their compliance protocols. Furthermore, states are increasingly applying heavy “sin taxes” to nicotine pouches as their popularity grows.

The Bottom Line

Nicotine pouches have firmly established themselves as a major player in the nicotine market. For the FDA and public health officials, the goal is a delicate balancing act: providing adult smokers with a legally regulated, less harmful alternative to combustible cigarettes, while aggressively ensuring these highly addictive products do not harm developing brains or fall into the hands of a new generation.